Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Change in Intangibles (2017 - 2019)

Historic Change in Intangibles for Amphastar Pharmaceuticals (AMPH) over the last 4 years, with Q1 2019 value amounting to $151000.0.

  • Amphastar Pharmaceuticals' Change in Intangibles fell 9656.82% to $151000.0 in Q1 2019 from the same period last year, while for Sep 2025 it was $151000.0, marking a year-over-year change of. This contributed to the annual value of $4.4 million for FY2018, which is 12000.0% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Change in Intangibles stood at $151000.0 for Q1 2019, which was down 9656.82% from $4.4 million recorded in Q1 2018.
  • In the past 5 years, Amphastar Pharmaceuticals' Change in Intangibles registered a high of $4.4 million during Q1 2018, and its lowest value of $151000.0 during Q1 2019.
  • In the last 3 years, Amphastar Pharmaceuticals' Change in Intangibles had a median value of $1.0 million in 2017 and averaged $1.6 million.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Change in Intangibles soared by 34000.0% in 2018, and later crashed by 9656.82% in 2019.
  • Amphastar Pharmaceuticals' Change in Intangibles (Quarter) stood at $1.0 million in 2017, then surged by 340.0% to $4.4 million in 2018, then crashed by 96.57% to $151000.0 in 2019.
  • Its Change in Intangibles was $151000.0 in Q1 2019, compared to $4.4 million in Q1 2018 and $1.0 million in Q2 2017.